

# Author Index Volume 3 (2016)

The issue number is given in front of the pagination

- Aartsma-Rus, A., see Hulsker, M. (1) 77–90
- Ahmed, R., see Argov, Z. (1) 49–66
- Alameddine, H.S. and J.E. Morgan, Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles (4) 455–473
- Allamand, V., see Cruz, S. (2) 267–274
- Almeida-Souza, L., see Bouhy, D. (2) 183–200
- Anderson, K.N., see West, S.D. (4) 529–537
- Antonini, G., see Garibaldi, M. (1) 111–114
- Argov, Z., Y. Caraco, H. Lau, A. Pestronk, P.B. Shieh, A. Skrinar, T. Koutsoukos, R. Ahmed, J. Martini and E. Kakkis, Aceneuramic Acid Extended Release Administration Maintains Upper Limb Muscle Strength in a 48-week Study of Subjects with GNE Myopathy: Results from a Phase 2, Randomized, Controlled Study (1) 49–66
- Arvanitidis, A., K. Henriksen, M.A. Karsdal and A. Nedergaard, Neo-epitope Peptides as Biomarkers of Disease Progression for Muscular Dystrophies and Other Myopathies (3) 333–346
- Atalaia, A., see West, S.D. (4) 529–537
- Audebert-Bellanger, S., see Grotto, S. (4) 487–495
- Auranen, M., see Ylikallio, E. (4) 475–485
- Azibani, F., see Ziat, E. (4) 497–510
- Badders, N.M., see Lanman, T.A. (1) 121–125
- Bakar, D., see Lanman, T.A. (1) 121–125
- Barghout, V., see Price, M.A. (1) 67–75
- Bartsakoulia, M., J.S. Müller, A. Gomez-Duran, P.Y.W. Man, V. Boczonadi and R. Horvath, Cysteine Supplementation May be Beneficial in a Subgroup of Mitochondrial Translation Deficiencies (3) 363–379
- Baudin, P.-Y., see Carlier, P.G. (1) 1–28
- Baudouin, S.V., see West, S.D. (4) 529–537
- Becane, H.-M., see Marey, I. (2) 227–245
- Behin, A., see Marey, I. (2) 227–245
- Benveniste, O., see Price, M.A. (1) 67–75
- Berrios, R.A., see Ramos, E. (2) 261–266
- Bertini, E., see Garibaldi, M. (1) 111–114
- Bertorini, T.E., see Punetha, J. (2) 209–225
- Bertrand, A.T., see Ziat, E. (4) 497–510
- Beuvin, M., see Ziat, E. (4) 497–510
- Bian, A., see Posner, A.D. (1) 91–99
- Biasini, F., see Rodolico, C. (3) 413–418
- Bierry, G., see Rudolf, G. (2) 275–281
- Boczonadi, V., see Bartsakoulia, M. (3) 363–379
- Böhm, J., see Garibaldi, M. (1) 111–114
- Bonne, G., see Ziat, E. (4) 497–510
- Bönnemann, C.G., see Punetha, J. (2) 209–225
- Bott, L.C., see Lanman, T.A. (1) 121–125
- Bouhy, D., T. Geuens, V. De Winter, L. Almeida-Souza, I. Katona, J. Weis, T. Hochepied, S. Goossens, J.J. Haigh, S. Janssens and V. Timmerman, Characterization of New Transgenic Mouse Models for Two Charcot-Marie-Tooth-Causing HspB1 Mutations using the Rosa26 Locus (2) 183–200
- Boyer, F.C., see Marey, I. (2) 227–245
- Brandom, B.W., see Butala, B.N. (1) 115–119
- Buchkremer, S., J.A.G. Coraspe, J. Weis and A. Roos, *Sil1*-Mutant Mice Elucidate Chaperone Function in Neurological Disorders (2) 169–181
- Burke, A., see Lanman, T.A. (1) 121–125
- Burnette, W.B., see Posner, A.D. (1) 91–99
- Bushby, K., see Vry, J. (4) 517–527
- Butala, B.N., A. Kang, J. Guron and B.W. Brandom, Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual (1) 115–119
- Butchbach, M.E.R., see Edwards, J.D. (4) 511–515
- Campbell, C., see Prasad, M. (3) 405–412
- Caraco, Y., see Argov, Z. (1) 49–66
- Carlier, P.G., B. Marty, O. Scheidegger, P. Loureiro de Sousa, P.-Y. Baudin, E. Snezhko and D. Vlodavets, Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials (1) 1–28
- Carver, M.P., J.S. Charleston, C. Shanks, J. Zhang, M. Mense, A.K. Sharma, H. Kaur and P. Sazani, Toxicological Characterization of Exon

- Skipping Phosphorodiamidate Morpholino Oligomers (PMOs) in Non-human Primates (3) 381–393
- Castets, P., S. Frank, M. Sinnreich and M.A. Rüegg, “Get the Balance Right”: Pathological Significance of Autophagy Perturbation in Neuromuscular Disorders (2) 127–155
- Chadwick, J.A., see Lowe, J. (3) 395–404
- Chamova, T., see Vry, J. (4) 517–527
- Chardon, J.W., B.J. Jasmin, R. Kothary and R.J. Parks, Report on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy – September 24–26, 2015, Ottawa, Canada (3) 431–442
- Charleston, J.S., see Carver, M.P. (3) 381–393
- Chelly, J., see Marey, I. (2) 227–245
- Christopher-Stine, L., see Price, M.A. (1) 67–75
- Ciranni, A., see Rodolico, C. (3) 413–418
- Clarke, N.F., see Punetha, J. (2) 209–225
- Claustres, M., see Marey, I. (2) 227–245
- Conde, J.G., see Ramos, E. (2) 261–266
- Coraspe, J.A.G., see Buchkremer, S. (2) 169–181
- Corbett, A., see Price, M.A. (1) 67–75
- Cortes-Vicente, E., see Cruz, S. (2) 267–274
- Cossee, M., see Marey, I. (2) 227–245
- Crowe, K.E., G. Shao, K.M. Flanigan and P.T. Martin, N-terminal  $\alpha$  Dystroglycan ( $\alpha$ DG-N): A Potential Serum Biomarker for Duchenne Muscular Dystrophy (2) 247–260
- Cruz, S., S. Figueiroa-Bonaparte, E. Gallardo, A. de Becdelièvre, C. Gartioux, V. Allamand, P. Piñol, M.A.R. Garcia, C. Jiménez-Mallebriera, J. Llauger, L. González-Rodríguez, E. Cortes-Vicente, I. Illa and J. Díaz-Manera, Bethlem Myopathy Phenotypes and Follow Up: Description of 8 Patients at the Mildest End of the Spectrum (2) 267–274
- Cuisset, J.-M., see Grotto, S. (4) 487–495
- de Becdelièvre, A., see Cruz, S. (2) 267–274
- de los Angeles Beytía, M., see Vry, J. (4) 517–527
- de Visser, M., see Price, M.A. (1) 67–75
- De Winter, V., see Bouhy, D. (2) 183–200
- Deburgrave, N., see Marey, I. (2) 227–245
- DeMuro, C., see Price, M.A. (1) 67–75
- Denning, C., see Kalra, S. (3) 309–332
- Desguerre, I., see Grotto, S. (4) 487–495
- Desguerre, I., see Marey, I. (2) 227–245
- Díaz-Manera, J., see Cruz, S. (2) 267–274
- Doerken, S., see Vry, J. (4) 517–527
- Donkervoort, S., see Punetha, J. (2) 209–225
- Drunat, S., see Grotto, S. (4) 487–495
- Echaniz-Laguna, A., see Rudolf, G. (2) 275–281
- Echigoya, Y., see Rodrigues, M. (1) 29–48
- Edwards, J.D. and M.E.R. Butchbach, Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy (4) 511–515
- Eichinger, K., K. Odrzywolski, J. Sowden and D.N. Herrmann, Patient Reported Falls and Balance Confidence in Individuals with Charcot-Marie-Tooth Disease (2) 289–292
- Evilä, A., see Papadimas, G.K. (2) 283–288
- Evilä, A., see Rudolf, G. (2) 275–281
- Eymard, B., see Marey, I. (2) 227–245
- Fattori, F., see Garibaldi, M. (1) 111–114
- Fauré, J., see Marty, I. (4) 443–453
- Faure, P., see Grotto, S. (4) 487–495
- Ferrer, X., see Marey, I. (2) 227–245
- Figueroa-Bonaparte, S., see Cruz, S. (2) 267–274
- Fischbeck, K.H., see Lanman, T.A. (1) 121–125
- Flanigan, K.M., see Crowe, K.E. (2) 247–260
- Floyd, K.T., see Lowe, J. (3) 395–404
- Flurin, V., see Grotto, S. (4) 487–495
- Frank, S., see Castets, P. (2) 127–155
- Frébourg, T., see Grotto, S. (4) 487–495
- Fukada, S., see Rodrigues, M. (1) 29–48
- Furlong, M.J., see Mulroy, E. (3) 419–423
- Gallardo, E., see Cruz, S. (2) 267–274
- Garami, M., see Vry, J. (4) 517–527
- Garcia, L., see Goyenvalle, A. (2) 157–167
- Garcia, M.A.R., see Cruz, S. (2) 267–274
- Garibaldi, M., J. Böhm, F. Fattori, C. Koch, C. Surace, P. Ottaviani, F. Laschena, J. Laporte, E. Bertini, G. Antonini and N.B. Romero, Novel Dominant Mutation in *BIN1* Gene Causing Mild Centronuclear Myopathy Revealed by Myalgias and CK Elevation (1) 111–114
- Gartioux, C., see Cruz, S. (2) 267–274
- Geuens, T., see Bouhy, D. (2) 183–200
- Ghaoui, R., see Punetha, J. (2) 209–225
- Giri, M., see Punetha, J. (2) 209–225
- Girlanda, P., see Rodolico, C. (3) 413–418
- Gleeson, S., see Mulroy, E. (3) 419–423
- Gómez, O., see Ramos, E. (2) 261–266
- Gomez-Duran, A., see Bartsakoulia, M. (3) 363–379
- Gomez-Sánchez, C.E., see Lowe, J. (3) 395–404

- Gomez-Sanchez, E.P., see Lowe, J. (3) 395–404  
 González-Rodríguez, L., see Cruz, S. (2) 267–274  
 Goossens, S., see Bouhy, D. (2) 183–200  
 Goyenvalle, A., C. Leumann and L. Garcia, Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides (2) 157–167  
 Gramsch, K., see Vry, J. (4) 517–527  
 Grebille, A.-G., see Grotto, S. (4) 487–495  
 Grotto, S., J.-M. Cuisset, S. Marret, S. Drunat, P. Faure, S. Audebert-Bellanger, I. Desguerre, V. Flurin, A.-G. Grebille, A.-M. Guerrot, H. Journel, G. Morin, G. Plessis, S. Renolleau, J. Roume, B. Simon-Bouy, R. Touraine, M. Willems, T. Frébourg, E. Verspyck and P. Saugier-Veber, Type 0 Spinal Muscular Atrophy: Further Delineation of Prenatal and Postnatal Features in 16 Patients (4) 487–495  
 Grunseich, C., see Lanman, T.A. (1) 121–125  
 Guergueltcheva, V., see Vry, J. (4) 517–527  
 Guerrot, A.-M., see Grotto, S. (4) 487–495  
 Guron, J., see Butala, B.N. (1) 115–119  
 Hackman, P., see Rudolf, G. (2) 275–281  
 Hackman, P., see Savarese, M. (3) 293–308  
 Haigh, J.J., see Bouhy, D. (2) 183–200  
 Harmison, G.G., see Lanman, T.A. (1) 121–125  
 Hausmanowa-Petrusewicz, I., see Punetha, J. (2) 209–225  
 Heatwole, C., see Hunter, M. (3) 425–429  
 Henriksen, K., see Arvanitidis, A. (3) 333–346  
 Herczegfalvi, Á., see Vry, J. (4) 517–527  
 Herrmann, D.N., see Eichinger, K. (2) 289–292  
 Hicks, R., see Prasad, M. (3) 405–412  
 Hilton-Jones, D., see Price, M.A. (1) 67–75  
 Hocepied, T., see Bouhy, D. (2) 183–200  
 Hoffman, E.P., see Punetha, J. (2) 209–225  
 Horvath, R., see Bartsakoulia, M. (3) 363–379  
 Hughes, J., see West, S.D. (4) 529–537  
 Hulsker, M., I. Verhaart, L. van Vliet, A. Aartsma-Rus and M. van Putten, Accurate Dystrophin Quantification in Mouse Tissue; Identification of New and Evaluation of Existing Methods (1) 77–90  
 Hunter, M., C. Heatwole, E. Luebbe and N.E. Johnson, What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients (3) 425–429  
 Illa, I., see Cruz, S. (2) 267–274  
 Ito, N., N. Shimizu, H. Tanaka and S. Takeda, Enhancement of Satellite Cell Transplantation Efficiency by Leukemia Inhibitory Factor (2) 201–207  
 Janssen, P.M.L., see Lowe, J. (3) 395–404  
 Janssens, S., see Bouhy, D. (2) 183–200  
 Jasmin, B.J., see Chardon, J.W. (3) 431–442  
 Jiménez-Mallebriera, C., see Cruz, S. (2) 267–274  
 Joe, G.O., see Lanman, T.A. (1) 121–125  
 Johnson, N.E., see Hunter, M. (3) 425–429  
 Journel, H., see Grotto, S. (4) 487–495  
 Kadakia, F.K., see Lowe, J. (3) 395–404  
 Kakkis, E., see Argov, Z. (1) 49–66  
 Kalra, S., F. Montanaro and C. Denning, Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies? (3) 309–332  
 Kaminska, A., see Vry, J. (4) 517–527  
 Kang, A., see Butala, B.N. (1) 115–119  
 Kararizou, E., see Papadimas, G.K. (2) 283–288  
 Karcagi, V., see Vry, J. (4) 517–527  
 Karsdal, M.A., see Arvanitidis, A. (3) 333–346  
 Katona, I., see Bouhy, D. (2) 183–200  
 Kaur, H., see Carver, M.P. (3) 381–393  
 Kesari, A., see Punetha, J. (2) 209–225  
 Kirschner, J., see Vry, J. (4) 517–527  
 Kissel, J.T., see Price, M.A. (1) 67–75  
 Kiuru-Enari, S., see Ylikallio, E. (4) 475–485  
 Koch, C., see Garibaldi, M. (1) 111–114  
 Kokkinis, A., see Lanman, T.A. (1) 121–125  
 Kostera-Pruszczynk, A., see Vry, J. (4) 517–527  
 Kothary, R., see Chardon, J.W. (3) 431–442  
 Kousi, M., see Ylikallio, E. (4) 475–485  
 Koutsoukos, T., see Argov, Z. (1) 49–66  
 Laforet, P., see Marey, I. (2) 227–245  
 Lammens, M., see van der Sluijs, B.M. (1) 101–109  
 Lamminen, A., see Ylikallio, E. (4) 475–485  
 Lanman, T.A., D. Bakar, N.M. Badders, A. Burke, A. Kokkinis, J.A. Shrader, G.O. Joe, A.B. Schindler, L.C. Bott, G.G. Harmison, J.P. Taylor, K.H. Fischbeck and C. Grunseich, Sexual Reassignment Fails to Prevent Kennedy's Disease (1) 121–125  
 Lannes, B., see Rudolf, G. (2) 275–281  
 Laporte, J., see Garibaldi, M. (1) 111–114  
 Laschena, F., see Garibaldi, M. (1) 111–114  
 Lau, H., see Argov, Z. (1) 49–66  
 Lehesjoki, A.-E., see Ylikallio, E. (4) 475–485  
 Leturcq, F., see Marey, I. (2) 227–245  
 Leumann, C., see Goyenvalle, A. (2) 157–167

- Llauger, J., see Cruz, S. (2) 267–274
- Lloyd, T.E., see Price, M.A. (1) 67–75
- Lochmüller, H., see Vry, J. (4) 517–527
- Lochmüller, H., see West, S.D. (4) 529–537
- Löfberg, M., see Ylikallio, E. (4) 475–485
- Loureiro de Sousa, P., see Carlier, P.G. (1) 1–28
- Lowe, J., K.T. Floyd, N. Rastogi, E.J. Schultz, J.A. Chadwick, S.A. Swager, J.G. Zins, F.K. Kadakia, S. Smart, E.P. Gomez-Sánchez, C.E. Gomez-Sánchez, S.V. Raman, P.M.L. Janssen and J.A. Rafael-Fortney, Similar Efficacy from Specific and Non-Specific Mineralocorticoid Receptor Antagonist Treatment of Muscular Dystrophy Mice (3) 395–404
- Luebbe, E., see Hunter, M. (3) 425–429
- Lundberg, I.E., see Price, M.A. (1) 67–75
- Lusakowska, A., see Vry, J. (4) 517–527
- MacKay, M., see Prasad, M. (3) 405–412
- Mahjneh, I., see Ylikallio, E. (4) 475–485
- Mamchaoui, K., see Ziat, E. (4) 497–510
- Man, PYW., see Bartsakoulia, M. (3) 363–379
- Manta, P., see Papadimas, G.K. (2) 283–288
- Marey, I., R.B. Yaou, N. Deburgrave, A. Vasson, J. Nectoux, F. Leturcq, B. Eymard, P. Laforet, A. Behin, T. Stojkovic, M. Mayer, V. Tiffreau, I. Desguerre, F.C. Boyer, A. Nadaj-Pakleza, X. Ferrer, K. Wahbi, H.-M. Becane, M. Claustres, J. Chelly and M. Cossee, Non Random Distribution of *DMD* Deletion Breakpoints and Implication of Double Strand Breaks Repair and Replication Error Repair Mechanisms (2) 227–245
- Marini-Bettolo, C., see West, S.D. (4) 529–537
- Markham, L.W., see Posner, A.D. (1) 91–99
- Marret, S., see Grotto, S. (4) 487–495
- Martin, P.T., see Crowe, K.E. (2) 247–260
- Martinisi, J., see Argov, Z. (1) 49–66
- Marty, B., see Carlier, P.G. (1) 1–28
- Marty, I. and J. Fauré, Excitation-Contraction Coupling Alterations in Myopathies (4) 443–453
- Mastaglia, F., see Price, M.A. (1) 67–75
- Mayer, M., see Marey, I. (2) 227–245
- Mense, M., see Carver, M.P. (3) 381–393
- Messina, S., see Rodolico, C. (3) 413–418
- Meyrick, J., see Walklet, E. (3) 347–362
- Montanaro, F., see Kalra, S. (3) 309–332
- Morgan, J.E., see Alameddine, H.S. (4) 455–473
- Morin, G., see Grotto, S. (4) 487–495
- Moss, T., see Walklet, E. (3) 347–362
- Mozaffar, T., see Price, M.A. (1) 67–75
- Mrazova, L., see Vry, J. (4) 517–527
- Müller, J.S., see Bartsakoulia, M. (3) 363–379
- Mulroy, E., S. Gleeson and M.J. Furlong, Stress-Induced Ketoacidosis in Spinal Muscular Atrophy: An Under-Recognized Complication (3) 419–423
- Muse, K., see Walklet, E. (3) 347–362
- Musumeci, O., see Rodolico, C. (3) 413–418
- Muurinen, T., see Ylikallio, E. (4) 475–485
- Nadaj-Pakleza, A., see Marey, I. (2) 227–245
- Nectoux, J., see Marey, I. (2) 227–245
- Nedergaard, A., see Arvanitidis, A. (3) 333–346
- Needham, M., see Price, M.A. (1) 67–75
- Nelson, I., see Ziat, E. (4) 497–510
- Nguyen, C.-T., see Prasad, M. (3) 405–412
- North, K.N., see Punetha, J. (2) 209–225
- O’Grady, G.L., see Punetha, J. (2) 209–225
- Oates, E.C., see Punetha, J. (2) 209–225
- Odrzywolski, K., see Eichinger, K. (2) 289–292
- Ottaviani, P., see Garibaldi, M. (1) 111–114
- Paetau, A., see Ylikallio, E. (4) 475–485
- Papadimas, G.K., A. Evilä, C. Papadopoulos, E. Kararizou, P. Manta and B. Udd, GNE-Myopathy in a Greek Romani Family with Unusual Calf Phenotype and Protein Aggregation Pathology (2) 283–288
- Papadopoulos, C., see Papadimas, G.K. (2) 283–288
- Pardo, S., see Ramos, E. (2) 261–266
- Parisi, D., see Rodolico, C. (3) 413–418
- Parks, R.J., see Chardon, J.W. (3) 431–442
- Pavlovská, L., see Vry, J. (4) 517–527
- Penttilä, S., see Rudolf, G. (2) 275–281
- Pestronk, A., see Argov, Z. (1) 49–66
- Piirilä, P., see Ylikallio, E. (4) 475–485
- Piñol, P., see Cruz, S. (2) 267–274
- Plessis, G., see Grotto, S. (4) 487–495
- Plotz, P.H., see Punetha, J. (2) 209–225
- Portaro, S., see Rodolico, C. (3) 413–418
- Posner, A.D., J.H. Soslow, W.B. Burnette, A. Bian, A. Shintani, D.B. Sawyer and L.W. Markham, The Correlation of Skeletal and Cardiac Muscle Dysfunction in Duchenne Muscular Dystrophy (1) 91–99
- Prasad, M., R. Hicks, M. MacKay, C.-T. Nguyen and C. Campbell, Developmental Milestones and Quality of Life Assessment in a Congenital Myotonic Dystrophy Cohort (3) 405–412
- Price, M.A., V. Barghout, O. Benveniste, L. Christopher-Stine, A. Corbett, M. de Visser, D. Hil-

- ton-Jones, J.T. Kissel, T.E. Lloyd, I.E. Lundberg, F. Mastaglia, T. Mozaffar, M. Needham, J. Schmidt, K. Sivakumar, C. DeMuro and B.S. Tseng, Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA (1) 67–75
- Punetha, J., A. Kesari, P. Uapinyoying, M. Giri, N.F. Clarke, L.B. Waddell, K.N. North, R. Ghaoui, G.L. O’Grady, E.C. Oates, S.A. Sandaradura, C.G. Bönnemann, S. Donkervoort, P.H. Plotz, E.C. Smith, C. Tesi-Rocha, T.E. Bertorini, M.A. Tarnopolsky, B. Reitter, I. Hausmanowa-Petrusewicz and E.P. Hoffman, Targeted Re-Sequencing Emulsion PCR Panel for Myopathies: Results in 94 Cases (2) 209–225
- Rafael-Fortney, J.A., see Lowe, J. (3) 395–404
- Rahbek, J., see Vry, J. (4) 517–527
- Raman, S.V., see Lowe, J. (3) 395–404
- Ramos, E., J.G. Conde, R.A. Berrios, S. Pardo, O. Gómez and M.F.M. Rodríguez, Prevalence and Genetic Profile of Duchene and Becker Muscular Dystrophy in Puerto Rico (2) 261–266
- Rastogi, N., see Lowe, J. (3) 395–404
- Raz, V., see van der Sluijs, B.M. (1) 101–109
- Reitter, B., see Punetha, J. (2) 209–225
- Renolleau, S., see Grotto, S. (4) 487–495
- Rodger, S., see Vry, J. (4) 517–527
- Rodolico, C., D. Parisi, S. Portaro, F. Biasini, S. Sinicropi, A. Ciranni, A. Toscano, S. Messina, O. Musumeci, G. Vita and P. Girlanda, Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls (3) 413–418
- Rodrigues, M., Y. Echigoya, S. Fukada and T. Yokota, Current Translational Research and Murine Models For Duchenne Muscular Dystrophy (1) 29–48
- Rodríguez, M.F.M., see Ramos, E. (2) 261–266
- Romero, N.B., see Garibaldi, M. (1) 111–114
- Roos, A., see Buchkremer, S. (2) 169–181
- Roume, J., see Grotto, S. (4) 487–495
- Rudolf, G., T. Suominen, S. Penttilä, P. Hackman, A. Evilä, B. Lannes, A. Echaniz-Laguna, G. Bierry, C. Tranchant and B. Udd, Homozygosity of the Dominant Myotilin c.179C>T (p.Ser60Phe) Mutation Causes a More Severe and Proximal Muscular Dystrophy (2) 275–281
- Rüegg, M.A., see Castets, P. (2) 127–155
- Salmi, T., see Ylikallio, E. (4) 475–485
- Sandaradura, S.A., see Punetha, J. (2) 209–225
- Sarparanta, J., see Savarese, M. (3) 293–308
- Saugier-Veber, P., see Grotto, S. (4) 487–495
- Savarese, M., J. Sarparanta, A. Vihola, B. Udd and P. Hackman, Increasing Role of Titin Mutations in Neuromuscular Disorders (3) 293–308
- Sawyer, D.B., see Posner, A.D. (1) 91–99
- Sazani, P., see Carver, M.P. (3) 381–393
- Scheidegger, O., see Carlier, P.G. (1) 1–28
- Schindler, A.B., see Lanman, T.A. (1) 121–125
- Schmidt, J., see Price, M.A. (1) 67–75
- Schröder, C.D., see van Groenestijn, A.C. (4) 539–544
- Schultz, E.J., see Lowe, J. (3) 395–404
- Shanks, C., see Carver, M.P. (3) 381–393
- Shao, G., see Crowe, K.E. (2) 247–260
- Sharma, A.K., see Carver, M.P. (3) 381–393
- Shieh, P.B., see Argov, Z. (1) 49–66
- Shimizu, N., see Ito, N. (2) 201–207
- Shintani, A., see Posner, A.D. (1) 91–99
- Shrader, J.A., see Lanman, T.A. (1) 121–125
- Simon-Bouy, B., see Grotto, S. (4) 487–495
- Sinicropi, S., see Rodolico, C. (3) 413–418
- Sinnreich, M., see Castets, P. (2) 127–155
- Sivakumar, K., see Price, M.A. (1) 67–75
- Skrinar, A., see Argov, Z. (1) 49–66
- Smart, S., see Lowe, J. (3) 395–404
- Smith, E.C., see Punetha, J. (2) 209–225
- Snezhko, E., see Carlier, P.G. (1) 1–28
- Soslow, J.H., see Posner, A.D. (1) 91–99
- Sowden, J., see Eichinger, K. (2) 289–292
- Spuler, S., see Ziat, E. (4) 497–510
- Steffensen, B.F., see Vry, J. (4) 517–527
- Stojkovic, T., see Marey, I. (2) 227–245
- Strenkova, J., see Vry, J. (4) 517–527
- Suominen, T., see Rudolf, G. (2) 275–281
- Surace, C., see Garibaldi, M. (1) 111–114
- Swager, S.A., see Lowe, J. (3) 395–404
- Takeda, S., see Ito, N. (2) 201–207
- Tanaka, H., see Ito, N. (2) 201–207
- Tarnopolsky, M.A., see Punetha, J. (2) 209–225
- Tassoni, A., see Vry, J. (4) 517–527
- Taylor, J.P., see Lanman, T.A. (1) 121–125
- Tesi-Rocha, C., see Punetha, J. (2) 209–225
- Thompson, R., see Vry, J. (4) 517–527
- Tiffreau, V., see Marey, I. (2) 227–245
- Timmerman, V., see Bouhy, D. (2) 183–200
- Toscano, A., see Rodolico, C. (3) 413–418
- Touraine, R., see Grotto, S. (4) 487–495
- Tournev, I., see Vry, J. (4) 517–527
- Tranchant, C., see Rudolf, G. (2) 275–281
- Träskelin, A.-L., see Ylikallio, E. (4) 475–485
- Tseng, B.S., see Price, M.A. (1) 67–75

- Uapinyoying, P., see Punetha, J. (2) 209–225
- Udd, B., see Papadimas, G.K. (2) 283–288
- Udd, B., see Rudolf, G. (2) 275–281
- Udd, B., see Savarese, M. (3) 293–308
- van den Berg, L.H., see van Groenestijn, A.C. (4) 539–544
- van den Heuvel, L.P., see van der Sluijs, B.M. (1) 101–109
- van der Sluijs, B.M., V. Raz, M. Lammens, L.P. van den Heuvel, N.C. Voermans and B.G.M. van Engelen, Intranuclear Aggregates Precede Clinical Onset in Oculopharyngeal Muscular Dystrophy (1) 101–109
- van Engelen, B.G.M., see van der Sluijs, B.M. (1) 101–109
- van Groenestijn, A.C., O. Verschuren, C.D. Schröder, L.H. van den Berg and J.M.A. Visser-Meily, The Åstrand-Ryhming Test is not a Feasible Measure in Ambulatory Patients with Amyotrophic Lateral Sclerosis (4) 539–544
- van Putten, M., see Hulsker, M. (1) 77–90
- van Vliet, L., see Hulsker, M. (1) 77–90
- Vasson, A., see Marey, I. (2) 227–245
- Verhaart, I., see Hulsker, M. (1) 77–90
- Verschuren, O., see van Groenestijn, A.C. (4) 539–544
- Verspyck, E., see Grotto, S. (4) 487–495
- Vihola, A., see Savarese, M. (3) 293–308
- Visser-Meily, J.M.A., see van Groenestijn, A.C. (4) 539–544
- Vita, G., see Rodolico, C. (3) 413–418
- Vlodavets, D., see Carlier, P.G. (1) 1–28
- Voermans, N.C., see van der Sluijs, B.M. (1) 101–109
- Vondráček, P., see Vry, J. (4) 517–527
- Vry, J., K. Gramsch, S. Rodger, R. Thompson, B.F. Steffensen, J. Rahbek, S. Doerken, A. Tassoni, M. de los Angeles Beytía, V. Guergueltcheva, T. Chamova, I. Tournev, A. Kostera-Pruszczyk, A. Kaminska, A. Lusakowska, L. Mrazova, L. Pavlovska, J. Strenkova, P. Vondráček, M.
- Garami, V. Karcagi, Á. Herczegfalvi, K. Bushby, H. Lochmüller and J. Kirschner, European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences (4) 517–527
- Waddell, L.B., see Punetha, J. (2) 209–225
- Wahbi, K., see Marey, I. (2) 227–245
- Walklet, E., K. Muse, J. Meyrick and T. Moss, Do Psychosocial Interventions Improve Quality of Life and Wellbeing in Adults with Neuromuscular Disorders? A Systematic Review and Narrative Synthesis (3) 347–362
- Weis, J., see Bouhy, D. (2) 183–200
- Weis, J., see Buchkremer, S. (2) 169–181
- West, S.D., H. Lochmüller, J. Hughes, A. Atalaia, C. Marini-Bettolo, S.V. Baudouin and K.N. Anderson, Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study (4) 529–537
- Willem, M., see Grotto, S. (4) 487–495
- Yaou, R.B., see Marey, I. (2) 227–245
- Ylikallio, E., M. Auranen, I. Mahjneh, A. Lamminen, M. Kousi, A.-L. Träskelin, T. Muurinen, M. Löfberg, T. Salmi, A. Paetau, A.-E. Lehesjoki, P. Piirilä and S. Kiuru-Enari, Decreased Aerobic Capacity in ANO5-Muscular Dystrophy (4) 475–485
- Yokota, T., see Rodrigues, M. (1) 29–48
- Zhang, J., see Carver, M.P. (3) 381–393
- Ziat, E., K. Mamchaoui, M. Beuvin, I. Nelson, F. Azibani, S. Spuler, G. Bonne and A.T. Bertrand, FHL1B Interacts with Lamin A/C and Emerin at the Nuclear Lamina and is Misregulated in Emery-Dreifuss Muscular Dystrophy (4) 497–510
- Zins, J.G., see Lowe, J. (3) 395–404